Saskia Neuteboom
- Biotechnology top 2%
- Hematology top 5%
- Multiple Myeloma Research and Treatments 6
- Molecular Biology top 5%
- Ubiquitin and proteasome pathways 23
- Glycosylation and Glycoproteins Research 6
- Oncology top 5%
- Cancer-related Molecular Pathways 8
- Peptidase Inhibition and Analysis 7
- Pancreatic and Hepatic Oncology Research 5
- Pharmacology top 5%
-
- Phagocytosis and Immune Regulation 5
-
- Renal cell carcinoma treatment 4
- Co-authors
- Michael A. PalladinoBenjamin NicholsonTa‐Hsiang ChaoCornelis MurreG. Kenneth LloydBarbara C. M. PottsRama Rao ManamKin S. Lam
- Journals
- Proceedings of the National Academy of Sciences (2 papers)The Journal of Experimental Medicine (1 paper)Journal of Clinical Oncology (4 papers)
- Partner nations
- United StatesAustraliaJapan
In The Last Decade
Saskia Neuteboom
52 papers receiving 2.3k citations
Hit Papers
Peers
Comparison fields: 5 of 100
- Biotechnology 310
- Hematology 350
- Molecular Biology 1.8k
- Oncology 596
- Pharmacology 339
Countries citing papers authored by Saskia Neuteboom
This map shows the geographic impact of Saskia Neuteboom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saskia Neuteboom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saskia Neuteboom more than expected).
Fields of papers citing papers by Saskia Neuteboom
This network shows the impact of papers produced by Saskia Neuteboom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saskia Neuteboom. The network helps show where Saskia Neuteboom may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Saskia Neuteboom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2012 | 41 | |
| 4 | 2011 | 25 | |
| 5 | 2011 | 123 | |
| 6 | 2009 | 1 | |
| 7 | 2008 | 13 | |
| 8 | Phase 1 clinical trials of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas | 2007 | 1 |
| 9 | Pharmacodynamic profiling defines the significant biological activities of the novel proteasome inhibitor NPI-0052: Comparison with Velcade® (Bortezomib) | 2006 | 1 |
| 10 | 2005 | 201 | |
| 11 | 2003 | 5 | |
| 12 | 2003 | 58 | |
| 13 | 2002 | 19 | |
| 14 | 2001 | 7 | |
| 15 | 1997 | 60 | |
| 16 | 1995 | 91 | |
| 17 | 1993 | 11 | |
| 18 | 1988 | 12 | |
| 19 | 1987 | 36 | |
| 20 | 1986 | 43 |
About Saskia Neuteboom
Saskia Neuteboom is a scholar working on Oncology, Biotechnology and Hematology, having authored 53 papers that have together received 2.4k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (23 papers), Cancer-related Molecular Pathways (8 papers), Peptidase Inhibition and Analysis (7 papers), Glycosylation and Glycoproteins Research (6 papers), Multiple Myeloma Research and Treatments (6 papers), Pancreatic and Hepatic Oncology Research (5 papers), Phagocytosis and Immune Regulation (5 papers) and Renal cell carcinoma treatment (4 papers). The work is most often cited by research in Biotechnology (310 citations), Hematology (350 citations) and Molecular Biology (1.8k citations). Saskia Neuteboom has collaborated with scholars based in United States, Australia and Japan. Frequent co-authors include Michael A. Palladino, Benjamin Nicholson, Ta‐Hsiang Chao, Cornelis Murre, G. Kenneth Lloyd, Barbara C. M. Potts, Rama Rao Manam, Kin S. Lam, Paul G. Richardson and Yoshiaki Kiso. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.